Emergent BioSolutions Wins $56 Million Order for Vaccine Supply to US Government

MT Newswires Live

Sep 09

Emergent BioSolutions (EBS) said Tuesday it has won a $56 million additional order from the US government to supply ACAM2000, a vaccine for smallpox and Mpox.

The company said that this additional order is being executed through a contract modification and the deliveries are expected to begin this month.

It added that with this modification, the total projected sales for its vaccine and ancillary products is expected to be more than $120 million this year from a diverse base of customers.

Emergent BioSolutions said that this contract modification is under its existing 10-year contract with the Administration for Strategic Preparedness and Response at the United States Department of Health and Human Services.

Emergent BioSolutions shares were up close to 2% in recent premarket activity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2566692548"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2566692548\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2566692548?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-09 20:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2566692548","market":"sh","top_or_hot":-1,"title":"Emergent BioSolutions Wins $56 Million Order for Vaccine Supply to US Government","media":"MT Newswires Live","content":"<html><body><p> Emergent BioSolutions (EBS) said Tuesday it has won a $56 million additional order from the US government to supply ACAM2000, a vaccine for smallpox and Mpox.</p><p>The company said that this additional order is being executed through a contract modification and the deliveries are expected to begin this month.</p><p>It added that with this modification, the total projected sales for its vaccine and ancillary products is expected to be more than $120 million this year from a diverse base of customers.</p><p>Emergent BioSolutions said that this contract modification is under its existing 10-year contract with the Administration for Strategic Preparedness and Response at the United States Department of Health and Human Services.</p><p>Emergent BioSolutions shares were up close to 2% in recent premarket activity.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Emergent BioSolutions Wins $56 Million Order for Vaccine Supply to US Government</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEmergent BioSolutions Wins $56 Million Order for Vaccine Supply to US Government\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-09-09 20:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Emergent BioSolutions (EBS) said Tuesday it has won a $56 million additional order from the US government to supply ACAM2000, a vaccine for smallpox and Mpox.</p><p>The company said that this additional order is being executed through a contract modification and the deliveries are expected to begin this month.</p><p>It added that with this modification, the total projected sales for its vaccine and ancillary products is expected to be more than $120 million this year from a diverse base of customers.</p><p>Emergent BioSolutions said that this contract modification is under its existing 10-year contract with the Administration for Strategic Preparedness and Response at the United States Department of Health and Human Services.</p><p>Emergent BioSolutions shares were up close to 2% in recent premarket activity.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4583","symbol_name":"猴痘概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2566692548","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2566692548","pubTimestamp":1757419855,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Emergent BioSolutions  said Tuesday it has won a $56 million additional order from the US government to supply ACAM2000, a vaccine for smallpox and Mpox.The company said that this additional order is being executed through a contract modification and the deliveries are expected to begin this month.It added that with this modification, the total projected sales for its vaccine and ancillary products is expected to be more than $120 million this year from a diverse base of customers.Emergent BioSolutions said that this contract modification is under its existing 10-year contract with the Administration for Strategic Preparedness and Response at the United States Department of Health and Human Services.Emergent BioSolutions shares were up close to 2% in recent premarket activity.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4583":"猴痘概念","EBS":"Emergent Biosolutions","BK4139":"生物科技"},"translate_title":"Emergent BioSolutions赢得美国政府5600万美元疫苗供应订单","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EBS":1},"content_text":"Emergent BioSolutions (EBS) said Tuesday it has won a $56 million additional order from the US government to supply ACAM2000, a vaccine for smallpox and Mpox.The company said that this additional order is being executed through a contract modification and the deliveries are expected to begin this month.It added that with this modification, the total projected sales for its vaccine and ancillary products is expected to be more than $120 million this year from a diverse base of customers.Emergent BioSolutions said that this contract modification is under its existing 10-year contract with the Administration for Strategic Preparedness and Response at the United States Department of Health and Human Services.Emergent BioSolutions shares were up close to 2% in recent premarket activity.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"corporation,merge","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}